PACBNMSHealthcare·Medical Devices#56 in industry

Pacific Biosciences of California, Inc.

Reports in 10d· 2026-05-07

-38.1% · 90d

$1.59

+0.03 (+1.92%)

After-Hours $1.60(+0.01)

News

(2)

April 2026

Apr 23, 20264 days agoARSHealthcare

PACB Charts Growth Path with Revio Amid $216M Net Loss

PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC.

# 🧾 What This Document Is This is Pacific Biosciences' **Annual Report to Shareholders (ARS)**. Think of it as the company's "year in review" report card sent directly to its owners (shareholders). It's a comprehensive look back at the fiscal year, covering business performance, financial health, f

Read summaryView on SEC EDGAR

Apr 23, 20264 days agoDEF 14AHealthcare

PACB Shareholders to Vote on Four Key Proposals Including Equity Plan Expansion

PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC.

# 🧾 What This Document Is This is a **DEF 14A**, also known as a **Proxy Statement**. It's a formal document sent to shareholders before an annual meeting. Its job is to give you all the information you need to vote on important company decisions. 👉 **In simple terms:** Think of it as a detailed

Read summaryView on SEC EDGAR

Key Data

Market Cap$493.7M

Open$1.55

Prev Close$1.56

Day Range$1.53 – $1.68

52W Range$0.85 – $2.73

Volume7,212,967

P/E (TTM)—

EPS$-1.82

Dividend Yield—

Beta2.33

Revenue Growth13.80%

Price Target$2.38(+49.4%)

Next Earnings2026-05-07(10d)

Analyst Ratings

Buy8 analysts

Buy 4Hold 3Sell 1

About

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Healthcare · Medical Devices

485 employees

www.pacb.com